- Home
- » Tags
- » Lobeglitazone
Top View
- Specific Inhibition of the Distribution of Lobeglitazone to the Liver
- WO 2016/066668 Al 6 May 2016 (06.05.2016) P O P C T
- The Effect of Antidiabetic Medications on Non-Alcoholic Fatty Liver Disease
- (12) United States Patent (10) Patent No.: US 9,526,728 B2 Klein Et Al
- The Role of Lipid Sensing Nuclear Receptors (Ppars and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD
- WO 2017/093465 Al 8 June 2017 (08.06.2017) W P O P C T
- Effects of Three Thiazolidinediones on Metabolic Regulation and Cold-Induced Thermogenesis
- Synthetic and Natural Peroxisome Proliferator‑Activated Receptor (PPAR) Agonists As Candidates for the Therapy of the Metabolic Syndrome
- PPAR-Mediated Toxicology and Applied Pharmacology
- The Antidiabetic Drug Lobeglitazone Protects Mice from Lipogenesis-Induced Liver Injury Via Mechanistic Target of Rapamycin Complex 1 Inhibition
- Exploration and Development of PPAR Modulators in Health and Disease : an Update of Clinical Evidence
- SEC (Endocrinology & Metabolism) Made in Its 87Th Meeting Held On
- Theranostics in Vivo Liposomal Delivery of Pparα/Γ Dual Agonist
- Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
- Review Article
- Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor Γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
- Quantitative Structural Assessment of Graded Receptor Agonism
- The Following Content Was Supplied by the Authors As Supporting Material and Has Not Been Copy-Edited Or Verified by JBJS
- Current Drug Targets, 2018, 19, 663-673 REVIEW ARTICLE
- Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
- Biocatalyzed Synthesis of Antidiabetic Drugs: a Review
- WO 2017/095725 Al 8 June 2017 (08.06.2017) W P O P C T
- Diseases[Version 1; Peer Review: 2 Approved]
- Research Article Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice
- Exercise Testing in Individuals with Diabetes, Practical Considerations for Exercise Physiologists
- Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
- A Narrative Review of Potential Future Antidiabetic Drugs:Should We Expect More?
- The Journey of Thiazolidinediones As Modulators of Ppars for the Management of Diabetes: a Critical Review
- WO 2017/198177 Al 23 November 2017 (23.11.2017) W !P O PCT